Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

n November 2007.

"Since we announced our Action Agenda in 2003, we have been steadily building a strong, high-performance company for the long term," said Hassan. "We are seeing that the acquisition of OBS was a smart, pivotal move in our transformation journey."

Integration of OBS continues to progress well, as evidenced by the following highlights:

-- In the human prescription and animal health areas, the executive teams

and organizational structures are in place and operating at all levels;

-- Cost synergies are being realized;

-- In R&D, an extensive review of the pipeline portfolio is ongoing.

First Quarter 2008 Results

For the 2008 first quarter, Schering-Plough reported net income available to common shareholders of $253 million or 15 cents per common share on a GAAP basis. Earnings per common share for the 2008 first quarter would have been 53 cents on net income of $862 million on a reconciled basis, which excludes purchase accounting adjustments and acquisition-related items for the OBS acquisition and other specified items. For the 2007 first quarter, Schering-Plough reported net income available to common shareholders of $543 million or 36 cents per common share on a GAAP basis and 42 cents per common share on a reconciled basis.

GAAP net sales for the 2008 first quarter totaled $4.7 billion, including $1.3 billion as a result of the OBS acquisition. The overall sales increase of

56 percent includes the impact of the OBS net sales and a favorable impact of 7 percent from foreign exchange on stand-alone Schering-Plough sales.

Global cholesterol joint venture net sales, which include VYTORIN and ZETIA, totaled $1.2 billion in the 2008 first quarter. Schering-Plough does not record sales of its cholesterol joint venture with Merck as the venture is accounted for under the equity method. Including an adjustment of an assumed 50 percent of the global cholesterol joint ventur
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
(Date:5/20/2015)... May 20, 2015  Select Medical Corporation ("Select") ... Trade Commission granted early termination of the waiting ... of 1976, as amended, applicable to the acquisition ... a joint venture that Select has created with ... As previously announced, MJ Acquisition Corporation has signed ...
Breaking Biology Technology:uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... VRUS ) management will present at Cowen & ... 2008 at Boston Marriott,Copley Place in Boston, MA. Schaefer ... the company on Tuesday, March 18, 2008,from 3:55 PM ... access a simultaneous webcast of Mr. Price,s overview of ...
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") today ... 31, 2007. All results are in U.S.,dollars and prepared ... ended December 31, 2007, was $20.3 million or,$1.04 per ... $2.38,per basic and diluted share in 2006. The substantial ...
... MannKind,Corporation (Nasdaq: MNKD ) today issued the ... MannKind is absolutely committed to the continued development ... our small,patient-friendly Medtone(R) inhaler to deliver Technosphere(R) Insulin ... more closely matches the pattern,of insulin secretion seen ...
Cached Biology Technology:Pharmasset to Present at Cowen & Company's Health Care Conference on Tuesday, March 18th 2Oncothyreon reports full year and fourth quarter 2007 financial results 2Oncothyreon reports full year and fourth quarter 2007 financial results 3Oncothyreon reports full year and fourth quarter 2007 financial results 4Oncothyreon reports full year and fourth quarter 2007 financial results 5Oncothyreon reports full year and fourth quarter 2007 financial results 6Oncothyreon reports full year and fourth quarter 2007 financial results 7MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... the "Fingerprint Sensors Market in Smart Mobile Devices ... report believes that 2014 was a watershed year for ... introduction of ,Apple Pay,. Apple gave fingerprint sensors a ... payment service. Fingerprint sensors are a must-have feature in ...
(Date:5/10/2015)... 2015 Fingerprint Cards (FPC) has received ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... smartphone manufacturers in China . The order ... guidance of + 1 000 MSEK for 2015.   ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... breakthrough in sensing at Rice University could make finding signs ... light. The technique reported in the Journal ... better medications to treat the devastating disease. The lab ... naturally attach themselves to a collection of beta amyloid proteins ...
... including stomach, liver and colon, are far more common in ... in lifestyle, such as diet and smoking, may account for ... rooted in basic biological differences between men and women. ... that treating male mice with estrogen dramatically lowers their rates ...
... COLLEGE PARK, Md. -- A new University of ... the 2009 flu pandemic (H1N1) and a common type of ... flu viruses -- with the potential for creating a new ... but University of Maryland virologist Daniel Perez, who directed the ...
Cached Biology News:Molecules 'light up' Alzheimer's roots 2Molecules 'light up' Alzheimer's roots 3Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3When well-known flu strains 'hook up' dangerous progeny can result 2When well-known flu strains 'hook up' dangerous progeny can result 3
... results - with a modular approach to ... The ChemStation Plus NDS family provides modular ... and data management, giving you the flexibility ... labs needs now and that can grow ...
... 'Agilents GeneSpring Workgroup solution is ... managing and mining expression data in ... and is deployed in over 40 ... research organizations worldwide. GeneSpring Workgroup streamlines ...
... proteomic scale kinase profiling, quantitative measurement ... discovery research built on the flexible ... platform. These microarrays are available as ... Substrate - Peptide Microarray Service. ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences are ... is (amino to carboxy terminus): S(21) - S - M - ... - E - A - I - D - K - ... This peptide may be used for neutralization and control ...
Biology Products: